Clinical Trial Update: ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ELACESTRANT in CDK4/6 inhibitor-naive, ER-positive, HER2-negative metastatic breast cancer. The study is sponsored by Stemline…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Elacestrant (elacestrant)

Snippet

Sponsor: Stemline Therapeutics, Inc. | Conditions: Metastatic Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING